405 related articles for article (PubMed ID: 25971426)
21. Comparison of the diagnostic accuracy of 99 m-Tc-MDP bone scintigraphy and 18 F-FDG PET/CT for the detection of skeletal metastases.
Chang CY; Gill CM; Joseph Simeone F; Taneja AK; Huang AJ; Torriani M; Bredella MA
Acta Radiol; 2016 Jan; 57(1):58-65. PubMed ID: 25533313
[TBL] [Abstract][Full Text] [Related]
22. Improved detection of bone metastases from lung cancer in the thoracic cage using 5- and 1-mm axial images versus a new CT software generating rib unfolding images: comparison with standard ¹⁸F-FDG-PET/CT.
Homann G; Mustafa DF; Ditt H; Spengler W; Kopp HG; Nikolaou K; Horger M
Acad Radiol; 2015 Apr; 22(4):505-12. PubMed ID: 25586709
[TBL] [Abstract][Full Text] [Related]
23. Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases.
Iagaru A; Young P; Mittra E; Dick DW; Herfkens R; Gambhir SS
Clin Nucl Med; 2013 Jul; 38(7):e290-6. PubMed ID: 23455520
[TBL] [Abstract][Full Text] [Related]
24. Bone Marrow Metastasis Is an Early Stage of Bone Metastasis in Breast Cancer Detected Clinically by F18-FDG-PET/CT Imaging.
Al-Muqbel KM
Biomed Res Int; 2017; 2017():9852632. PubMed ID: 28884133
[TBL] [Abstract][Full Text] [Related]
25. 18F-FDG-PET/MR increases diagnostic confidence in detection of bone metastases compared with 18F-FDG-PET/CT.
Samarin A; Hüllner M; Queiroz MA; Stolzmann P; Burger IA; von Schulthess G; Veit-Haibach P
Nucl Med Commun; 2015 Dec; 36(12):1165-73. PubMed ID: 26397999
[TBL] [Abstract][Full Text] [Related]
26. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis.
Son SH; Lee SW; Jeong SY; Song BI; Chae YS; Ahn BC; Lee J
AJR Am J Roentgenol; 2015 Oct; 205(4):878-85. PubMed ID: 26204115
[TBL] [Abstract][Full Text] [Related]
27. A review on the added value of whole-body MRI in metastatic lobular breast cancer.
Bhaludin BN; Tunariu N; Koh DM; Messiou C; Okines AF; McGrath SE; Ring AE; Parton MM; Sharma B; Gagliardi T; Allen SD; Pope R; Johnston SRD; Downey K
Eur Radiol; 2022 Sep; 32(9):6514-6525. PubMed ID: 35384456
[TBL] [Abstract][Full Text] [Related]
28. The role of (18)F-FDG PET/CT in initial staging of patients with locally advanced breast carcinoma with an emphasis on M staging.
Mittal BR; Manohar K; Kashyap R; Bhattacharya A; Singh B; Singh G
Hell J Nucl Med; 2011; 14(2):135-9. PubMed ID: 21761015
[TBL] [Abstract][Full Text] [Related]
29. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
Ohara M; Shigematsu H; Tsutani Y; Emi A; Masumoto N; Ozaki S; Kadoya T; Okada M
Breast; 2013 Oct; 22(5):958-63. PubMed ID: 23756383
[TBL] [Abstract][Full Text] [Related]
30. Standardized Uptake Values from PET/MRI in Metastatic Breast Cancer: An Organ-based Comparison With PET/CT.
Pujara AC; Raad RA; Ponzo F; Wassong C; Babb JS; Moy L; Melsaether AN
Breast J; 2016 May; 22(3):264-73. PubMed ID: 26843433
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of Breast MRI and (18)F-FDG PET/CT for the Preoperative Staging of Invasive Lobular Carcinoma versus Ductal Carcinoma.
Jung NY; Kim SH; Kim SH; Seo YY; Oh JK; Choi HS; You WJ
J Breast Cancer; 2015 Mar; 18(1):63-72. PubMed ID: 25834613
[TBL] [Abstract][Full Text] [Related]
32. Comparison of (18) F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma.
Hurley C; McCarville MB; Shulkin BL; Mao S; Wu J; Navid F; Daw NC; Pappo AS; Bishop MW
Pediatr Blood Cancer; 2016 Aug; 63(8):1381-6. PubMed ID: 27082077
[TBL] [Abstract][Full Text] [Related]
33. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
34. Oncologic significance of unexpected osseous foci on FDG-PET without correlative CT abnormalities.
Zamora E; Valdivia AY
Ann Nucl Med; 2021 Mar; 35(3):347-359. PubMed ID: 33439440
[TBL] [Abstract][Full Text] [Related]
35. 18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT.
Piccardo A; Puntoni M; Morbelli S; Massollo M; Bongioanni F; Paparo F; Altrinetti V; Gonella R; Gennari A; Iacozzi M; Sambuceti G; DeCensi A
Nuklearmedizin; 2015; 54(4):163-72. PubMed ID: 26165806
[TBL] [Abstract][Full Text] [Related]
36. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer.
Song BI; Lee SW; Jeong SY; Chae YS; Lee WK; Ahn BC; Lee J
J Nucl Med; 2012 Sep; 53(9):1337-44. PubMed ID: 22870824
[TBL] [Abstract][Full Text] [Related]
37. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
38. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
Ak I; Sivrikoz MC; Entok E; Vardareli E
Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657
[TBL] [Abstract][Full Text] [Related]
39. Comparison of (18)F-FDG-PET/CT with (99m)Tc-MDP bone scintigraphy for the detection of bone metastases in cancer patients.
Ozülker T; Küçüköz Uzun A; Ozülker F; Ozpaçac T
Nucl Med Commun; 2010 Jun; 31(6):597-603. PubMed ID: 20224457
[TBL] [Abstract][Full Text] [Related]
40. Novel CT and scintigraphic findings of bone metastasis from invasive lobular breast cancer.
Al-Ogaili Z; Troedson R
J Med Imaging Radiat Oncol; 2016 Feb; 60(1):47-53. PubMed ID: 26549329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]